[1]李娜,张杰,高荣玉,等.单次注射康柏西普治疗渗出型AMD患者RPE隆起面积与容积变化[J].眼科新进展,2016,36(2):172-174.[doi:10.13389/j.cnki.rao.2016.0047]
　LI Na,ZHANG Jie,GAO Rong-Yu,et al.Changes of retinal pigment epithelium uplift area and volume in exudative age-related macular degeneration after once injection of conbercept[J].Recent Advances in Ophthalmology,2016,36(2):172-174.[doi:10.13389/j.cnki.rao.2016.0047]
点击复制

单次注射康柏西普治疗渗出型AMD患者RPE隆起面积与容积变化
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
36卷
期数:
2016年2期
页码:
172-174
栏目:
应用研究
出版日期:
2016-02-05

文章信息/Info

Title:
Changes of retinal pigment epithelium uplift area and volume in exudative age-related macular degeneration after once injection of conbercept
作者:
李娜; 张杰; 高荣玉; 孙先勇
261053　山东省潍坊市，潍坊医学院
Author(s):
LI Na ; ZHANG Jie ;  GAO Rong-Yu ; SUN Xian-Yong
Weifang Medical University,Weifang 261053,Shandong Province,China
关键词:
渗出型年龄相关性黄斑变性; 康柏西普; 视网膜色素上皮
Keywords:
exudative age-related macular degeneration ;  conbercept;  retinal pigment epithelium
DOI:
10.13389/j.cnki.rao.2016.0047
文献标志码:
A
摘要:
目的　观察单次玻璃体内注射康柏西普治疗渗出型年龄相关性黄斑变性（ａｇｅ-ｒｅｌａｔｅｄｍａｃｕｌａｒｄｅｇｅｎｅｒａｔｉｏｎ，ＡＭＤ）患者的视网膜色素上皮（ｒｅｔｉｎａｌｐｉｇｍｅｎｔｅｐｉｔｈｅｌｉｕｍ，ＲＰＥ）隆起的面积及容积变化，以评价康柏西普治疗ＡＭＤ的短期疗效及安全性。方法　选取渗出型ＡＭＤ患者４０例（４５眼），所有患者均行玻璃体内注射康柏西普０．０５ｍＬ（０．５ｍｇ）治疗。术前、术后１周、１个月及３个月复诊行Ｃｉｒｒｕｓ５０００ＯＣＴ检查，比较治疗前后最佳矫正视力（ｂｅｓｔｃｏｒｒｅｃｔｅｄｖｉｓｕａｌａｃｕｉｔｙ，ＢＶＣＡ）、黄斑中心凹厚度及ＲＰＥ隆起的面积、容积。结果　术后１周、１个月，ＢＣＶＡ（ｌｏｇＭＡＲ）由术前１．２５±０．７９分别提升至０．９２±０．６６（Ｐ＜０．００１）和０．９４±０．６１（Ｐ＜０．００１），３ｍｍ圆内ＲＰＥ隆起面积及容积由术前的（２．９１±１．７３）ｍｍ２、（０．５０±０．７３）ｍｍ３分别降至（２．７５±１．８２）ｍｍ２（Ｐ＝０．０２４）、（０．４２±０．７１）ｍｍ３（Ｐ＝０．０２０）和（２．３３±１．８５）ｍｍ２（Ｐ＝０．００２）、（０．３２±０．０９）ｍｍ３（Ｐ＝０．０４６）。术后３个月时ＢＣＶＡ下降至１．３０±０．８２，与术前差异无统计学意义（Ｐ＞０．０５）；３ｍｍ圆内ＲＰＥ隆起面积及容积增加到（２．７３±１．８１）ｍｍ２、（０．５１±０．７９）ｍｍ３，与术前相比差异均无统计学意义（均为Ｐ＞０．０５）。术后１周、１个月、３个月５ｍｍ圆内ＲＰＥ隆起面积及容积与术前差异均无统计学意义（均为Ｐ＞０．０５）。黄斑中心凹厚度仅在术后１个月由术前（２４４．５６±２５．３７）μｍ降至（２３４．９１±２１．５０）μｍ（Ｐ＝０．０４４）。所有患者均未出现严重眼部并发症及全身不良反应。结论　康柏西普短期内治疗渗出型ＡＭＤ可显著提高视力，恢复视网膜结构，具有良好的安全性。
Abstract:
Objective To evaluate the changes of retinal pigment epithelium (RPE) uplift area and volume in exudative age-related macular degeneration ( AMD) after once injection of conbercept, and evaluate the short-term efficacy and safety of conbercept for AMD. Methods Forty patients (45 eyes) with exudative AMD were chosen , and all cases adopt conbercept injection (0. 5 mL ,0. 5 mg) . The changes of central macular retinal thickness ( CMT) and RPE uplift in area and volume at the preoperation and postoperative I week, I month and 3 months were detected by Cirrus 5000 OCT , and the best corrected visual acuity ( BCVA) was also examined. Results At I week and I month after treatment , BCVA was improved from l. 25 +0. 79 preoperatively t0 0. 92 + 0. 66 .0. 94 +0. 61 ( all P < 0. 001) ; Within 3 mm in circle RPE uplift in area and volume were respectively dropped from (2. 91 + 1. 73 ) mm2 . (0. 50 + 0. 73 ) mm3 to (2. 75 + 1. 82) mm’ (P = 0. 024) . ( 0. 42 + 0. 71 ) mm3 (P = 0. 020 ) and ( 2. 33 + 1. 85 ) mm2 (P = 0. 002) . ( 0. 32 + 0. 09 ) mmJ ( P = 0. 046 ) . At 3 months after treatment , BCVA was dropped t0 1. 30 +0. 82; Within 3 mm in circle RPE uplift area and volume were improved to ( 2. 73 + 1. 81 ) mm2 . ( 0. 51 + 0. 79 ) mmJ , there was no statistically sigruficant difference compared with pre-operation ( all P > 0. 05 ) . There was no statistically significant difference in within 5 mm in circle RPE uplift area and volume compared with preoperation ( all P > 0. 05 ) . CMT was dropped from ( 244. 56 + 25 . 37 ) Vm preoperatively to ( 234. 91 + 21. 50) Vm at I month after treatment ( P = 0. 044 ) . Severe ocular complication and systenuc adverse reaction has not been found. Conclusion Conbercept can improve BCVA sigruficantly and restore the structure of retina with good security for AMD in short-term.

相似文献/References:

[1]王永波 石安娜 刘维锋 石浔 金昱.光动力疗法治疗渗出性年龄相关性黄斑变性的疗效观察[J].眼科新进展,2012,32(1):000.
[2]陆秉文 吴星伟. 苦碟子注射液联合光动力疗法与玻璃体内注射Ranibizumab治疗渗出型年龄相关性黄斑变性[J].眼科新进展,2014,34(3):268.
[3]张娣,张玲,杨静,等.玻璃体内注射康柏西普联合手术及全视网膜光凝治疗新生血管性青光眼[J].眼科新进展,2015,35(12):1170.[doi:10.13389/j.cnki.rao.2015.0320]
　ZHANG Di,ZHANG Ling,YANG Jing,et al.Intravitreal injection of conbercept combined with operation and panretinal photocoagulation for neovascular glaucoma[J].Recent Advances in Ophthalmology,2015,35(2):1170.[doi:10.13389/j.cnki.rao.2015.0320]
[4]王琛,李东豪,闻毅颐.玻璃体内注射康柏西普联合周边视网膜选择性光凝治疗视网膜静脉阻塞继发黄斑水肿的疗效及安全性[J].眼科新进展,2016,36(5):471.[doi:10.13389/j.cnki.rao.2016.0126]
　WANG Chen,LI Dong-Hao,WEN Yi-Yi.Intravitreal injection of conbercept combined with selective peripheral retinal photocoagulation for macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2016,36(2):471.[doi:10.13389/j.cnki.rao.2016.0126]
[5]王玮,徐玲娟,蔡苏博,等.角膜基质及结膜下单次注射康柏西普治疗角膜新生血管的疗效及安全性[J].眼科新进展,2016,36(8):725.[doi:10.13389/j.cnki.rao.2016.0192]
　WANG Wei,XU Lin-Juan,CAI Su-Bo,et al.Efficacy and safety of one dose intrastromal and subconjunctival conbercept injection for corneal neovascularization[J].Recent Advances in Ophthalmology,2016,36(2):725.[doi:10.13389/j.cnki.rao.2016.0192]
[6]史志洁,张金嵩,吕晓贝.玻璃体内注射康柏西普联合手术治疗伴玻璃体积血的新生血管性青光眼[J].眼科新进展,2016,36(8):751.[doi:10.13389/j.cnki.rao.2016.0200]
　SHI Zhi-Jie,ZHANG Jin-Song,LV Xiao-Bei.Intravitreal injection of conbercept and surgical treatment for neovascular glaucoma combined with vitreous hemorrhage[J].Recent Advances in Ophthalmology,2016,36(2):751.[doi:10.13389/j.cnki.rao.2016.0200]
[7]罗顺利,许泽广,梁春正.复合式小梁切除术联合康柏西普治疗新生血管性青光眼[J].眼科新进展,2016,36(11):1076.[doi:10.13389/j.cnki.rao.2016.0287]
　LUO Shun-Li,XU Ze-Guang,LIANG Chun-Zheng.Compound trabeculectomy with conbercept for neovascular glaucoma[J].Recent Advances in Ophthalmology,2016,36(2):1076.[doi:10.13389/j.cnki.rao.2016.0287]
[8]吴若欣,徐洁慧,温积全,等.玻璃体内注射康柏西普对渗出性老年性黄斑变性患者脉络膜厚度的影响[J].眼科新进展,2016,36(12):1172.[doi:10.13389/j.cnki.rao.2016.0312]
　WU Ruo-Xin,XU Jie-Hui,WEN Ji-Quan,et al.Effects of intravitreal conbercept injections on choroidal thickness in exudative age-related macular degeneration[J].Recent Advances in Ophthalmology,2016,36(2):1172.[doi:10.13389/j.cnki.rao.2016.0312]
[9]薛鹏程,游志鹏,付书华,等.23G玻璃体切割术前、术中辅助玻璃体内注射康柏西普治疗增生型糖尿病视网膜病变（PDR）的疗效分析[J].眼科新进展,2017,37(5):458.[doi:10.13389/j.cnki.rao.2017.0116]
　XUE Peng-Cheng,YOU Zhi-Peng,FU Shu-Hua,et al.Preoperative and intraoperative adjunctive intravitreal conbercept in 23G vitrectomy for proliferative diabetic retinopathy[J].Recent Advances in Ophthalmology,2017,37(2):458.[doi:10.13389/j.cnki.rao.2017.0116]
[10]朱磊,田晓燕,刘涛.玻璃体内注射康柏西普治疗湿性年龄相关性黄斑变性的临床观察[J].眼科新进展,2017,37(5):473.[doi:10.13389/j.cnki.rao.2017.0120]
　ZHU Lei,TIAN Xiao-Yan,LIU Tao.Intravitreal injection of conbercept for wet age-related macular degeneration[J].Recent Advances in Ophthalmology,2017,37(2):473.[doi:10.13389/j.cnki.rao.2017.0120]

更新日期/Last Update: 2016-01-29